Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Abstract 4179: Potent and selective TRK inhibitor CH7057288

Hiroshi Tanaka, Hitoshi Sase, Toshiyuki Tsukaguchi, Hiromi Tanimura, Masami Hasegawa, Kiyoshi Hasegawa, Yoshiyuki Ono, Nobuhiro Oikawa, Hiroshi Sakamoto, Toshiyuki Mio

Cancer Res (2017) 77 (13_Supplement): 4179.

https://doi.org/10.1158/1538-7445.AM2017-4179

Published: 01 July 2017

View articletitled, Abstract 4179: Potent and selective TRK inhibitor CH7057288

Journal Articles

Abstract 773: Alectinib shows potent antitumor activity against both ALK- and RET-rearranged non-small cell lung cancers

Tatsushi Kodama, Toshiyuki Tsukaguchi, Yasuko Satoh, Miyuki Yoshida, Yoshiaki Watanabe, Osamu Kondoh, Hiroshi Sakamoto

Cancer Res (2015) 75 (15_Supplement): 773.

https://doi.org/10.1158/1538-7445.AM2015-773

Published: 01 August 2015

View articletitled, Abstract 773: Alectinib shows potent antitumor activity against both ALK- and RET-rearranged non-small cell lung cancers

Journal Articles

Abstract 3853: Unique pattern of copy number changes including chromothripsis in pulmonary adenocarcinoma with EML4-ALK fusion

Hironori Ninomiya, Motohiro Kato, Seishi Ogawa, Noriko Motoi, Kengo Takeuchi, Tatsushi Kodama, Hiroshi Sakamoto, Nobuya Ishii, Mutsunori Fujiwara, Yuichi Ishikawa

Cancer Res (2015) 75 (15_Supplement): 3853.

https://doi.org/10.1158/1538-7445.AM2015-3853

Published: 01 August 2015

View articletitled, Abstract 3853: Unique pattern of copy number changes including chromothripsis in pulmonary adenocarcinoma with EML4-ALK fusion

Journal Articles

Abstract 754: Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases

Tatsushi Kodama, Toshiyuki Tsukaguchi, Masami Hasegawa, Miyuki Yoshida, Kenji Takanashi, Osamu Kondoh, Hiroshi Sakamoto

Cancer Res (2014) 74 (19_Supplement): 754.

https://doi.org/10.1158/1538-7445.AM2014-754

Published: 01 October 2014

View articletitled, Abstract 754: Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases

Journal Articles

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Nobuya Ishii, Naoki Harada, Eric W. Joseph, Kazuhiro Ohara, Takaaki Miura, Hiroshi Sakamoto, Yutaka Matsuda, Yasushi Tomii, Yukako Tachibana-Kondo, Hitoshi Iikura, Toshihiro Aoki, Nobuo Shimma, Mikio Arisawa, Yoshihiro Sowa, Poulikos I. Poulikakos, Neal Rosen, Yuko Aoki, Toshiyuki Sakai

Cancer Res (2013) 73 (13): 4050–4060.

https://doi.org/10.1158/0008-5472.CAN-12-3937

Published: 30 June 2013

View articletitled, Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Includes: Supplementary data

Journal Articles

Abstract 2192: A novel mechanism of EML4-ALK rearrangement in a patient-derived cell line and its tumor growth inhibition by an ALK inhibitor CH5424802.

Tatsushi Kodama, Noriko Motoi, Hironori Ninomiya, Hiroshi Sakamoto, Kunio Kitada, Toshiyuki Tsukaguchi, Yasuko Sato, Nobuya Ishii, Yasuhito Terui, Kiyohiko Hatake, Yuichi Ishikawa

Cancer Res (2013) 73 (8_Supplement): 2192.

https://doi.org/10.1158/1538-7445.AM2013-2192

Published: 15 April 2013

View articletitled, Abstract 2192: A novel mechanism of EML4-ALK rearrangement in a patient-derived cell line and its tumor growth inhibition by an ALK inhibitor CH5424802.

Journal Articles

Abstract DDT01-02: CH5424802: A selective ALK inhibitor

Hiroshi Sakamoto, Nobuhiro Oikawa, Takuo Tsukuda, Nobuo Shimma, Nobuya Ishii, Yuko Aoki

Cancer Res (2011) 71 (8_Supplement): DDT01-02.

https://doi.org/10.1158/1538-7445.AM2011-DDT01-02

Published: 15 April 2011

View articletitled, Abstract DDT01-02: CH5424802: A selective ALK inhibitor

Journal Articles

Abstract 3559: A new selective ALK inhibitor CH5424802 shows potent efficacy against ALK-positive cancers including the gatekeeper mutant-driven tumors

Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, Takaaki A. Fukami, Nobuhiro Oikawa, Takuo Tsukuda, Nobuya Ishii, Yuko Aoki

Cancer Res (2011) 71 (8_Supplement): 3559.

https://doi.org/10.1158/1538-7445.AM2011-3559

Published: 15 April 2011

View articletitled, Abstract 3559: A new selective ALK inhibitor CH5424802 shows potent efficacy against ALK-positive cancers including the gatekeeper mutant-driven tumors

Journal Articles

Abstract 3593: Generation of a potent and selective inhibitor of ALK, CH5424802, showing superior oral bioavailability, PK profile and in vivo efficacy

Nobuhiro Oikawa, Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Itoh, Hatsuo Kawada, Sosuke Hara, Takuho Miyagi, Jun Ohwada, Saori Taniguchi, Kazuo Hattori, Takuo Tsukuda, Kenji Takanashi, Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Nobuya Ishii, Yuko Aoki, Nobuo Shimma

Cancer Res (2011) 71 (8_Supplement): 3593.

https://doi.org/10.1158/1538-7445.AM2011-3593

Published: 15 April 2011

View articletitled, Abstract 3593: Generation of a potent and selective inhibitor of ALK, CH5424802, showing superior oral bioavailability, PK profile and in vivo efficacy

Journal Articles

Abstract 3606: CH5126766 is a novel allosteric inhibitor of MEK that prevents its phosphorylation by RAF

Nobuya Ishii, Naoki Harada, Hiroshi Sakamoto, Yutaka Matsuda, Yasushi Tomii, Yukako Tachibana-Kondo, Takaaki Miura, Kazuhiro Ohara, Hitoshi Iikura, Toshihiro Aoki, Nobuo Shimma, Mikio Arisawa, Eric Joseph, Poulikos Poulikakos, Yoshihiro Sowa, Neal Rosen, Yuko Aoki, Toshiyuki Sakai

Cancer Res (2011) 71 (8_Supplement): 3606.

https://doi.org/10.1158/1538-7445.AM2011-3606

Published: 15 April 2011

View articletitled, Abstract 3606: CH5126766 is a novel allosteric inhibitor of MEK that prevents its phosphorylation by RAF

Journal Articles

Abstract #3701: CH4987655 (RO4987655), a selective orally bioavailable MEK inhibitor, shows highly potent and broad antitumor activity as a monotherapy and in combination with other antitumor agents

Satoshi Aida, Yasushi Yoshimura, Nobuya Ishii, Hiroshi Sakamoto, Yoshiaki Isshiki, Yuji Ishikawa, Masanori Miwa, Nobuo Shimma, Hisafumi Okabe, Yuko Aoki

Cancer Res (2009) 69 (9_Supplement): 3701.

Published: 01 May 2009

View articletitled, Abstract #3701: CH4987655 (RO4987655), a selective orally bioavailable MEK inhibitor, shows highly potent and broad antitumor activity as a monotherapy and in combination with other antitumor agents

Journal Articles

Abstract #2920: Pharmacodynamic response of CH4987655 (RO4987655), a potent and selective orally bioavailable MEK inhibitor, in preclinical models.

Yasushi Yoshimura, Nobuya Ishii, Hiroshi Sakamoto, Takaaki Miura, Yoshiaki Isshiki, Yuji Ishikawa, Masanori Miwa, Nobuo Shimma, Hisafumi Okabe, Yuko Aoki

Cancer Res (2009) 69 (9_Supplement): 2920.

Published: 01 May 2009

View articletitled, Abstract #2920: Pharmacodynamic response of CH4987655 (RO4987655), a potent and selective orally bioavailable MEK inhibitor, in preclinical models.

Journal Articles

Predominant Suppression of Apoptosome by Inhibitor of Apoptosis Protein in Non-Small Cell Lung Cancer H460 Cells: Therapeutic Effect of a Novel Polyarginine-conjugated Smac Peptide

Liling Yang, Tetsuo Mashima, Shigeo Sato, Mikiko Mochizuki, Hiroshi Sakamoto, Takao Yamori, Tomoko Oh-hara, Takashi Tsuruo

Cancer Res (2003) 63 (4): 831–837.

Published: 15 February 2003

View articletitled, Predominant Suppression of Apoptosome by Inhibitor of Apoptosis Protein in Non-Small Cell Lung Cancer H460 Cells: Therapeutic Effect of a Novel Polyarginine-conjugated Smac Peptide

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 4179: Potent and selective TRK inhibitor CH7057288

Abstract 773: Alectinib shows potent antitumor activity against both ALK- and RET-rearranged non-small cell lung cancers

Abstract 3853: Unique pattern of copy number changes including chromothripsis in pulmonary adenocarcinoma with EML4-ALK fusion

Abstract 754: Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Abstract 2192: A novel mechanism of EML4-ALK rearrangement in a patient-derived cell line and its tumor growth inhibition by an ALK inhibitor CH5424802.

Abstract DDT01-02: CH5424802: A selective ALK inhibitor

Abstract 3559: A new selective ALK inhibitor CH5424802 shows potent efficacy against ALK-positive cancers including the gatekeeper mutant-driven tumors

Abstract 3593: Generation of a potent and selective inhibitor of ALK, CH5424802, showing superior oral bioavailability, PK profile and in vivo efficacy

Abstract 3606: CH5126766 is a novel allosteric inhibitor of MEK that prevents its phosphorylation by RAF

Abstract #3701: CH4987655 (RO4987655), a selective orally bioavailable MEK inhibitor, shows highly potent and broad antitumor activity as a monotherapy and in combination with other antitumor agents

Abstract #2920: Pharmacodynamic response of CH4987655 (RO4987655), a potent and selective orally bioavailable MEK inhibitor, in preclinical models.

Predominant Suppression of Apoptosome by Inhibitor of Apoptosis Protein in Non-Small Cell Lung Cancer H460 Cells: Therapeutic Effect of a Novel Polyarginine-conjugated Smac Peptide

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only